On ECHEMI
Home > Drugs > Hainan Brilliant Pharmaceutical Co., Ltd.
Hainan Brilliant Pharmaceutical Co., Ltd.
  • Founded in:

    2004-07-29
  • Country:

    China China
  • Address:

    No. 4, Yaogu 1st Road, Haikou National High-tech Industrial Development Zone, Haikou City
  • Tax NO.:

    914600007603794713
  • Registered Funds:

    12.27100815 million yuan
  • Email:

Related Drugs
Sodium phosphate oral solution
The main ingredients of this product and their chemical names are: disodium hydrogen phosphate, sodium dihydrogen phosphate
Name Description Content CAS NO. Registered Holders
Sodium Phosphate, Dibasic

Distends the lower intestine to stimulate the defecation reflex and facilitates stool excretion by increasing the water content of the stool

More

Distends the lower intestine to stimulate the defecation reflex and facilitates stool excretion by increasing the water content of the stool

7558-79-4 19
Sodium dihydrogen phosphate

Distends the lower intestine to stimulate the defecation reflex and facilitates stool excretion by increasing the water content of the stool

More

Distends the lower intestine to stimulate the defecation reflex and facilitates stool excretion by increasing the water content of the stool

89140-32-9 9
Acyclovir Injection
The main ingredient of this product is acyclovir.
Name Description Content CAS NO. Registered Holders
Acyclovir

In vitro, it has an inhibitory effect on herpes simplex virus, varicella zoster virus, cytomegalovirus, etc. The drug is easily taken up by herpes simplex virus, then phosphorylated into triphosphate, which inhibits viral replication in two ways: interfering with viral DNA polymerase and inhibiting viral replication; under the action of DNA polymerase, it binds to the growing DNA chain, causing the extension of the DNA chain to be interrupted.

More

In vitro, it has an inhibitory effect on herpes simplex virus, varicella zoster virus, cytomegalovirus, etc. The drug is easily taken up by herpes simplex virus, then phosphorylated into triphosphate, which inhibits viral replication in two ways: interfering with viral DNA polymerase and inhibiting viral replication; under the action of DNA polymerase, it binds to the growing DNA chain, causing the extension of the DNA chain to be interrupted.

59277-89-3 50
Ozagrel Sodium for Injection
Ozagrel sodium.
Name Description Content CAS NO. Registered Holders
Ozagrel sodium

This product is a thromboxane synthetase inhibitor that can inhibit the production of TXA2, thus having the effects of anti-platelet aggregation and vasodilation. Animal experiments have shown that intravenous administration can reduce plasma TXB2 levels and the Keto-PGF12/TXB2 ratio, inhibit platelet aggregation caused by different inducers, and prevent cerebral infarction caused by the middle cerebral artery in rats.

More

This product is a thromboxane synthetase inhibitor that can inhibit the production of TXA2, thus having the effects of anti-platelet aggregation and vasodilation. Animal experiments have shown that intravenous administration can reduce plasma TXB2 levels and the Keto-PGF12/TXB2 ratio, inhibit platelet aggregation caused by different inducers, and prevent cerebral infarction caused by the middle cerebral artery in rats.

189224-26-8 10
Ozagrel Sodium for Injection
Ozagrel sodium.
Name Description Content CAS NO. Registered Holders
Ozagrel sodium

This product is a thromboxane synthetase inhibitor that can inhibit the production of TXA2, thus having the effects of anti-platelet aggregation and vasodilation. Animal experiments have shown that intravenous administration can reduce plasma TXB2 levels and the Keto-PGF12/TXB2 ratio, inhibit platelet aggregation caused by different inducers, and prevent cerebral infarction caused by the middle cerebral artery in rats.

More

This product is a thromboxane synthetase inhibitor that can inhibit the production of TXA2, thus having the effects of anti-platelet aggregation and vasodilation. Animal experiments have shown that intravenous administration can reduce plasma TXB2 levels and the Keto-PGF12/TXB2 ratio, inhibit platelet aggregation caused by different inducers, and prevent cerebral infarction caused by the middle cerebral artery in rats.

189224-26-8 10
Clindamycin Hydrochloride for Injection
Clindamycin hydrochloride.
Name Description Content CAS NO. Registered Holders
Clindamycin hydrochloride

21462-39-5 34
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.